

**Survival in a Contemporary, Real-World Cohort of Patients With Mixed-Phenotype
Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From
THAOS**

Jonas Wixner¹, Angela Dispenzieri², Leslie Amass³, Martin Carlsson³, Steve Riley⁴, Evan Powers⁵,
Jeffery W Kelly⁵, on behalf of the THAOS investigators

¹Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; ²Division of Hematology, Mayo Clinic, Rochester, MN, USA; ³Pfizer Inc, New York, NY, USA; ⁴Pfizer Inc, Groton, CT, USA; ⁵Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA

Corresponding author: Jonas Wixner, Department of Medicine, Umeå University Hospital, Akutvägen 1, S-90185 Umeå, Sweden; E-mail: jonas.wixner@umu.se

Supplementary Table S1 Ethics committees

AEMPS - Agencia Espanola de Medicamentos y Product Calle Campezo 1-Edificio 8 Madrid, 28022 SPAIN
Azienda Ospedaliera Policlinico S.Orsola Malpighi Bologna, 40100 ITALY
Comitato Etico AOU Bologna Policlinico S. Orsola Segreteria Scientifica Comitato Etico Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, 15 Bologna, 40138 ITALY
Biomedical Research Alliance of New York 1981 Marcus Ave,Ste 210 New Hyde Park, NY 11042 UNITED STATES
CCTIRS Secrétaire Générale du Comité,1 rue Descartes Paris Cedex 05, NA 75231 FRANCE
CEIC Illes Balears C/ de Jesús, 38,Conselleria de Salut, Família i Benestar Social Palma, 07010 SPAIN
Centro Hospitalar de Lisboa Norte, EPE - Hospital Santa Maria Av. Prof. Egas Moniz Lisboa, 1649-035 PORTUGAL
Hospital Santo Antonio Servicio De Endocrinologia,Largo Prof. Abel Salazar

<p>Portp, 4000</p> <p>PORTUGAL</p>
<p>Cleveland Clinic Abu Dhabi Research Ethics Committee (REC)</p> <p>Office of Clinical Research</p> <p>PO Box 112412, N/A, N/A</p> <p>Abu Dhabi, N/A</p> <p>UNITED ARAB EMIRATES</p>
<p>Colorado Multiple Institute Review Board</p> <p>13001 E 17th Place,Rm N3214</p> <p>Aurora, CO 80010</p> <p>UNITED STATES</p>
<p>Comisión de Ética en Investigación</p> <p>Vasco de Quiroga Num. 15, Tlalpan, Instituto Nacional de Ciencias Médicas y Nutrición</p> <p>Mexico, D.F. 14000</p> <p>MEXICO</p>
<p>Comissão de ética do CHAA</p> <p>Rua dos Cutileiros, Creixomil</p> <p>Guimarães, 4835-044</p> <p>PORTUGAL</p>
<p>Comite consultatif sur le traitement de l'information en matiere de recherche dans le domaine</p> <p>1 rue Descartes,Secrétaire Générale du Comité</p> <p>Paris Cedex 05, 75231</p> <p>FRANCE</p>
<p>Comite consultatif sur le traitement de l'</p> <p>information en matiere de recherche dans le domaine de la sante, 1,rue descartes</p> <p>Paris cedex 05, 75231</p> <p>FRANCE</p>
<p>Commission Nationale de informatique et des libert</p> <p>8.rue vivienne, CS 30223</p> <p>Paris cedex 02, 75083</p> <p>FRANCE</p>

<p>Comité de Ética IDIM Alfredo Lanari Av. Combatientes de Malvinas 3150 Ciudad Autónoma de Buenos Aires, CP 1427 ARGENTINA</p>
<p>CONEP (Comissao Nacional de Etica em Pesquisa) SRTV 701, Via W 5 Norte, Lote D, Edificio PO 700, 3 andar - Asa Norte Brasilia, DF 70719-040 BRAZIL</p>
<p>Comite de Etica em Pesquisa do Instituto Dante Pazzanese de Cardiologia Avenida Dr. Dante Pazzanese, 500, 8 Andar Ibirapuera Sao Paulo, SAO PAULO 04012-180 BRAZIL</p>
<p>Conjoint Health Research Ethics Board 2500 University Drive NW,3rd Floor MacKimmie Tower Calgary, AB T2N 1N4 CANADA</p>
<p>CPP Ile de France IX 51 Ave du Marechal de Lattre de Tassigny, Pr Roudot-Thoraval, CHU Henri Mondor Créteil, 94010 FRANCE</p>
<p>Ethics Committee Careggi Firenze Nuovo Ingresso Careggi (NIC) - Didattica, pad. 3 - Largo Brambilla, 3, Rosina Cerbelli Firenze, 50134 ITALY</p>
<p>Ethics Committee for Multicenter Trials Ministry of health, 5 Sveta Nedelia Square Sofia, 1000 BULGARIA</p>
<p>Ethikkommission - Ethikausschuss am Campus Virchow-Klinikum EC Chariteplatz 1</p>

<p>Berlin, 10117</p> <p>GERMANY</p>
<p>Ethikkommission an der medizinischen Fakultät</p> <p>Pauwelsstr. 30 Ethik-Kommission an der medizinischen Fakultät, der rheinisch-westfälischen technischen Hochschule Aa</p> <p>Aachen, 52074</p> <p>GERMANY</p>
<p>Fondazione Policlinico Universitario A. Gemelli Università Cattolica del S. Cuore</p> <p>Largo Agostino Gemelli 8</p> <p>Roma, 00168</p> <p>ITALY</p>
<p>Hospital Santo Antonio</p> <p>Servicio De Endocrinologia, Largo Prof. Abel Salazar</p> <p>Porto, 4000</p> <p>PORTUGAL</p>
<p>Hospital Universitario Clementino Fraga Filho - HU</p> <p>Rua Professor Rodolpho Paulo Rocco, 255</p> <p>Rio de Janeiro, 21941-913</p> <p>BRAZIL</p>
<p>IRB of Samsung Medical Center</p> <p>50 Irwon-ro, Gangnam-gu</p> <p>Seoul, 135-710</p> <p>KOREA, REPUBLIC OF</p>
<p>Johns Hopkins Medical IRB</p> <p>1620 McElderry Street Office of Human Subject Research, Reed Hall, Ste B-130</p> <p>Baltimore, MD 21205-1911</p> <p>UNITED STATES</p>
<p>Klinikum der Universität Heidelberg</p> <p>Zentrallabor</p> <p>Im Neuenheimer Feld</p>

<p>Heidelberg, 69120 GERMANY</p>
<p>Kumamoto University Ethical Review Committee 1-1-1, Honjo Kumamoto, TOKYO JAPAN</p>
<p>Mayo Clinic Institutional Review Board 200 First St SW Rochester, MN 55905 UNITED STATES</p>
<p>Medical College of Wisconsin/ Froedtert Hospital 9200 W Wisconsin Ave, Institutional Review Board Milwaukee, WI 53226 UNITED STATES</p>
<p>Medical Ethics Review Board_ University Medical Cen P.O. Box 30.001 GRONINGEN,, LA10 9700 RB NETHERLANDS</p>
<p>Medical Research Ethics Committee, University Malaya Medical Centre Lembah Pantai Kuala Lumpur, 59100 MALAYSIA</p>
<p>National Taiwan University Hospital No. 7, Chung-Shan South Road, R.O.C Taipei, 100 TAIWAN</p>
<p>Ochsner Institutional Review Board 1514 Jefferson Hwy New Orleans, LA 70121 UNITED STATES</p>

<p>Regional Ethics Committee for Clinical Trials of the Tuscany Region</p> <p>Santa Chiara Site, Via Roma 67, Technical Scientific Secretariat</p> <p>Pisa, GREATER NORTH WEST AREA 56126</p> <p>ITALY</p>
<p>Regionala etikprövningsnämnden i Umeå</p> <p>Samverkanshuset, Universitetsområdet</p> <p>Umeå, 901 87</p> <p>SWEDEN</p>
<p>Research Ethics Committee, King Faisal Specialist Hospital and Research Center</p> <p>Al Mathar Ash Shamali</p> <p>Riyadh, 11564</p> <p>SAUDI ARABIA</p>
<p>Romania Academy of Medical Sciences</p> <p>National Bioethics Committee of Medicines and Medical Devices</p> <p>Sos. Stefan cel Mare No. 19-21, Sector 2</p> <p>Bucharest, 020125</p> <p>ROMANIA</p>
<p>The Chaim Sheba Medical Center</p> <p>IRB Committee</p> <p>Sackler School of Medicine</p> <p>Tel-Hashomer, 5265601</p> <p>ISRAEL</p>
<p>University Health Network - Research Ethics Board</p> <p>700 University Avenue, 10th Floor - Room 1056</p> <p>Toronto, ON M5G 1Z5</p> <p>CANADA</p>
<p>University of Chicago Institutional Review Board</p> <p>5751 S Woodlawn Ave, 2nd Fl</p> <p>Chicago, IL 60637</p> <p>UNITED STATES</p>

<p>University of Maryland 800 W Baltimore Street Baltimore Human Research Protection Ofc (HRPO), Ste 100 Baltimore, MD 21201 UNITED STATES</p>
<p>University of Pennsylvania, Committee of Studies Involving Human Beings 3624 Market Street Office of Regulatory Affairs, Ste 301S Philadelphia, PA 19104-6006 UNITED STATES</p>
<p>University of Pittsburgh Human Resource HPRO 3500 Fifth Ave, Protection Ofc, Hieber Bldg, Main Ofc Ste 106 Pittsburgh, PA 15213 UNITED STATES</p>
<p>University of Utah Institutional Review Board 75 S 2000 E Salt Lake City, UT 84112 UNITED STATES</p>
<p>Unversitatsklinijum Munster Institut fur Klinische Chemie uns Laboratoriumsmedizin Albert Schweitzer StraBe 33 Munster, 48149 GERMANY</p>
<p>Vanderbilt Human Research Protection Program 1313 21st Ave S, 504 Oxford House Nashville, TN 37232-4315 UNITED STATES</p>
<p>Veterans Affairs Greater Los Angeles Institutional Review Board 11301 Wilshire Blvd Los Angeles, CA 90073 UNITED STATES</p>
<p>Washington University Human Research Protection Office 660 S Euclid Ave, MS0809-29-2300</p>

St. Louis, MO 63110

UNITED STATES

Western IRB

1019 39th Ave SE Ste 120

Puyallup, WA 98374

UNITED STATES

Yale Human Investigations Committee

55 College St

New Haven, CT 06510

UNITED STATES

Supplementary Table S2 Demographics and baseline clinical characteristics of patients with mixed-phenotype ATTR-CM enrolled in any year of THAOS.

	Tafamidis-treated (n = 156)	Untreated (n = 963)
Sex, n (%)		
Female	31 (19.9)	271 (28.1)
Male	125 (80.1)	692 (71.9)
Race/ethnicity^a, n (%)		
Afro-Caribbean	1 (0.6)	8 (0.8)
American Hispanic	1 (0.6)	2 (0.2)
Asian	6 (3.8)	62 (6.4)
Black or African American	25 (16.0)	118 (12.3)
Latino American	2 (1.3)	36 (3.7)
White	85 (54.5)	524 (54.4)
Other	0	35 (3.6)
Age at symptom onset (y)	<i>n</i> = 137	<i>n</i> = 911
Median (10 th , 90 th percentile)	66.5 (43.5, 82.0)	61.5 (33.8, 77.5)
Time from symptom onset to diagnosis (y)	<i>n</i> = 137	<i>n</i> = 822
Median (10 th , 90 th percentile)	4.6 (0.2, 19.2)	2.5 (0.0, 11.8)
Year of enrollment, n (%)		
2007–2012	3 (1.9)	280 (29.1)
2013–2018	37 (23.7)	460 (47.8)
2019–2023	116 (74.4)	223 (23.2)
Age at enrollment (y), median (10th, 90th percentile)	75.8 (63.3, 87.5)	69.6 (47.3, 82.3)
Symptom duration at enrollment (y)	<i>n</i> = 137	<i>n</i> = 911
Median (10 th , 90 th percentile)	6.7 (1.0, 20.0)	5.1 (1.0, 16.7)
Follow-up time^b (y), median (10th, 90th percentile)	1.6 (0.3, 5.5)	2.4 (0.4, 8.3)
TTR genotype, n (%)		
Variant	71 (45.5)	744 (77.3)

Wild-type	85 (54.5)	219 (22.7)
Most frequent ($\geq 10\%$) <i>TTR</i> variants ^d , <i>n</i> (%)		
V30M (p.V50M) ^e	9 (5.8)	318 (33.0)
V122I (p.V142I)	27 (17.3)	159 (16.5)
Heart failure, <i>n</i> (%)	127 (81.4)	715 (74.2)
NYHA class ^c , <i>n</i> (%)		
I	14 (11.0)	86 (12.0)
II	72 (56.7)	318 (44.5)
III	34 (26.8)	230 (32.2)
IV	3 (2.4)	34 (4.8)
NT-proBNP (pg/mL)	<i>n</i> = 50	<i>n</i> = 381
Median (10 th , 90 th percentile)	2323 (436.0, 9405.5)	2187 (220.0, 8905.0)
LV septum thickness (mm)	<i>n</i> = 109	<i>n</i> = 509
Median (10 th , 90 th percentile)	16.0 (13.0, 21.0)	17.0 (12.0, 22.0)
LV ejection fraction (%)	<i>n</i> = 110	<i>n</i> = 479
Median (10 th , 90 th percentile)	54.0 (30.0, 68.0)	52.0 (30.0, 67.0)
mBMI	<i>n</i> = 109	<i>n</i> = 572
Median (10 th , 90 th percentile)	1082 (867.0, 1425.8)	990.0 (730.6, 1286.2)
Past or current clinical trial participation ^f , <i>n</i> (%)		
Yes	28 (17.9)	132 (13.7)
Tafamidis trial	0	0
Non-tafamidis trial	28 (17.9)	132 (13.7)
No	128 (82.1)	623 (64.7)
Diagnostic method ^g , <i>n</i> (%)		
Clinical symptoms	152 (97.4)	829 (86.1)
Amyloid confirmed on tissue biopsy	71 (45.5)	519 (53.9)
TTR confirmed as precursor protein on tissue biopsy	63 (40.4)	343 (35.6)
Scintigraphy	88 (56.4)	146 (15.2)

Other	30 (19.2)	44 (4.6)
eGFR (mL/min/1.73m ²)	<i>n</i> = 60	<i>n</i> = 647
Median (10 th , 90 th percentile)	46.9 (10.6, 78.1)	61.6 (28.8, 105.2)
NAC stage, <i>n</i> (%)	<i>n</i> = 50	<i>n</i> = 361
I	22 (44.0)	188 (52.1)
II	16 (32.0)	117 (32.4)
III	12 (24.0)	56 (15.5)

The number of patients with recorded data shown for variables with missing data. Baseline refers to enrollment or tafamidis treatment initiation (whichever was later) for tafamidis-treated patients, and enrollment for untreated patients

eGFR estimated glomerular filtration rate, *LV* left ventricular, *mBMI* modified body mass index, *NAC* National Amyloidosis Centre, *NT-proBNP* N-terminal pro-B-type natriuretic peptide, *NYHA* New York Heart Association, *THAOS* Transthyretin Amyloidosis Outcomes Survey, *TTR* transthyretin

^a Race was not collected in France or Portugal

^b Follow-up time is based on consent date to last available follow-up date

^c Denominator is number of patients with heart failure; 4 tafamidis-treated patients and 47 untreated patients had missing data

^d One untreated patient had both the V30M and V122I variant and was counted in both groups

^e Includes patients with G6S (p.G26S) in addition to V30M

^f Missing for 208 untreated patients

^g Patients could be diagnosed based on >1 diagnostic method